Sexual health

Why Men Can't Get a Routine HPV Test

Save

Women get a validated HPV test as part of cervical cancer screening because decades of research built a reliable pathway from a positive test to a treatable pre-cancer. No comparable pathway exists yet for the sites HPV affects in men — a real limitation of current medicine, not evidence that testing men wouldn't help if the science existed.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why isn't there a routine HPV test for men?

There's no routine HPV test for men because the HPV testing that exists and is recommended is built around the cervix specifically — a test paired with decades of research showing exactly how a positive result maps to pre-cancer risk, and exactly what to do next (repeat testing, colposcopy, treatment) to keep it from progressing to cancer. That entire validated pathway doesn't exist yet for the anus, penis, or throat in the general population, which is where HPV causes cancer in men — and without a pathway from result to next step, there's no test to recommend. Approving one before that pathway exists could cause more harm than good, through false reassurance or procedures with no proven benefit.

This is a gap in what's been validated, not evidence that HPV doesn't matter for men, or that a positive result wouldn't be useful if the science caught up. It's also not permanent: some clinics already offer anal Pap testing for specific higher-risk groups, like men who have sex with men, particularly if HIV-positive, even though it isn't part of general-population guidelines.

What is HPV, and why does testing focus on the cervix?

Human papillomavirus is the most common sexually transmitted infection in the United States, and most infections — in anyone, of any sex — clear on their own without ever causing a symptom or a problem. Whether HPV causes cancer at all comes down to persistence: it's the infections that don't clear, particularly with certain high-risk HPV types, that can eventually progress to cancer, which is the entire reason HPV testing exists in the first place 1.

Cervical HPV testing works as a screening tool because how HPV causes cervical cancer is unusually well mapped: HPV infects cervical cells, can cause a defined, gradually progressing pre-cancerous change, and that change can be caught on a Pap test or HPV test and treated years before it would become cancer. Decades of research went into proving that pathway and building the testing and follow-up system around it. No other HPV-related cancer site has that same body of research behind it yet, which is the practical reason testing hasn't expanded there.

Where HPV causes cancer in men

HPV causes roughly 39,300 cancers in the United States each year, and while cervical cancer is the most common HPV-associated cancer in women, HPV throat cancer — oropharyngeal cancer, affecting the back of the mouth and throat — is the most common HPV-associated cancer in men 2. HPV can also cause penile and anal cancer in men, though both are considerably less common than throat cancer. These are sometimes grouped together as the HPV cancers beyond the cervix, since cervical cancer gets most of the public attention despite not being the only place HPV causes disease.

None of these cancers in men currently has a validated, general-population screening test the way cervical cancer does. That doesn't mean they're not taken seriously — it means the research base needed to justify a screening program, an accurate test, a defined pre-cancer stage, and proof that catching it early improves outcomes, hasn't been built for these sites yet, unlike the cervix.

A test not being routine isn't always about it not existing

It's tempting to assume any STI a clinician doesn't test for routinely simply doesn't have a test yet, but that's not always the reason. Genital herpes is a useful contrast: a blood test for HSV antibodies does exist and works, but national guidelines specifically recommend against using it as routine screening in people without symptoms, because in a low-risk population it produces enough false positives to cause more harm — anxiety, unnecessary treatment, strained relationships — than it prevents 3.

HPV in men has a different problem — a validated test and follow-up pathway mostly doesn't exist yet for the relevant sites — but the guiding principle is the same one applied to herpes: a test only becomes a routine recommendation once evidence shows, population-wide, that using it does more good than harm. Neither gap is arbitrary, even though both can feel, from the outside, like being overlooked.

This isn't the only screening gap for men

HPV isn't the only place national guidance treats men and women differently. For chlamydia and gonorrhea — both far more established, well-tested infections — national screening guidance recommends routine annual testing for sexually active women under 25, but states the evidence is currently insufficient to recommend the same routine screening for men without symptoms or other specific risk factors 4. That's not a statement that men can't get or don't need treatment for chlamydia and gonorrhea; it's a statement that research hasn't yet shown routine screening changes outcomes for men the way it has for women.

The pattern across these gaps is consistent: guidelines follow where the evidence is strongest, and for a range of historical and research-funding reasons, that evidence has been built out further for women's reproductive health than for a lot of men's sexual health. It's a real limitation, and one testing science is still catching up to.

What men can actually do without a routine test

Without a routine test to catch HPV early, prevention and awareness do more of the work. The HPV vaccine is the single most effective tool available: it's recommended routinely at ages 11 to 12, with catch-up vaccination through age 26, and it can still be considered through shared decision-making between ages 27 and 45 5. Getting vaccinated, even later than the routine window, still provides protection against the HPV types not yet encountered.

Condoms help but don't fully close the gap, because HPV spreads through skin-to-skin contact in areas a condom doesn't cover, not only through fluids — condoms are highly effective against STIs spread by genital fluids, but only partially protective against skin-to-skin infections like HPV 6. Beyond vaccination and condom use, paying attention to and reporting any unusual, persistent bump, sore, or change to a clinician, and keeping up with routine STI testing for the infections that do have one, remains the most practical way to stay ahead of a virus that, for men specifically, medicine still can't screen for directly.

Common questions

Not through a routine, guideline-recommended test the way women can as part of cervical cancer screening. Some clinics offer anal Pap testing for specific higher-risk groups, such as men who have sex with men or people living with HIV, but there's no general-population HPV test recommended for men the way there is for cervical screening.

Often he wouldn't, since most HPV infections cause no symptoms at all and clear on their own. The exception is genital warts, a visible sign of certain lower-risk HPV types, and any new bump, sore, or unusual change is worth having a clinician look at, whether or not it turns out to be HPV.

Yes — the vaccine protects against the specific HPV types it covers that a person hasn't yet been exposed to, and most people, even if sexually active, haven't encountered every type the vaccine protects against. It's recommended through age 26, and can still be considered between ages 27 and 45 through a conversation with a clinician.

Possibly — research into anal and oral HPV screening is ongoing, and testing already exists for specific higher-risk groups in some clinical settings. Whether it expands to general-population guidelines depends on building the same kind of evidence that supports cervical screening: an accurate test, a defined pre-cancer stage, and proof that catching it early actually improves outcomes.

It reflects an imbalance in the research, not a judgment about whose health matters more. Cervical cancer screening had decades of dedicated research behind it before it became routine; the equivalent research for the sites HPV affects in men, throat, penis, anus, is newer and less complete, a real gap in the science rather than an intentional omission.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Symptoms worth having checked, even without a routine test

  • —A sore, lump, or patch in the mouth or throat that doesn't heal within a few weeks
  • —Persistent hoarseness, difficulty swallowing, or a lump in the neck
  • —A new growth, wart, or sore on the penis or around the anus
  • —Unusual bleeding from the rectum

This article is educational and doesn't replace a clinical exam; a clinician can evaluate any unusual growth, sore, or persistent symptom directly.

References

  1. 1.Centers for Disease Control and Prevention (2024). Human Papillomavirus (HPV). CDC (cdc.gov/hpv). linkSupports that HPV is the most common STI in the U.S., that most infections clear on their own, and that persistent high-risk-type infection can progress to cancer.
  2. 2.Centers for Disease Control and Prevention (2024). Basic Information about HPV and Cancer. CDC (cdc.gov/cancer). linkSupports that HPV causes roughly 39,300 cancers per year in the U.S., including cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers, with oropharyngeal being the most common HPV-associated cancer in men.
  3. 3.US Preventive Services Task Force (2023). Genital Herpes Infection: Serologic Screening. US Preventive Services Task Force (reaffirmation, JAMA 2023). link ✓Supports that USPSTF recommends against routine serologic screening for genital herpes in asymptomatic adults because of poor test specificity and net harm, used here as an analogous example of a test being withheld from routine use for reasons beyond nonexistence.
  4. 4.US Preventive Services Task Force (2021). Chlamydia and Gonorrhea: Screening. US Preventive Services Task Force (final recommendation, JAMA 2021). link ✓Supports that USPSTF recommends routine chlamydia/gonorrhea screening for sexually active women 24 and younger but states evidence is insufficient to recommend the same routine screening for men, used to show HPV isn't the only sex-based STI screening gap.
  5. 5.Centers for Disease Control and Prevention (Advisory Committee on Immunization Practices) (2024). ACIP Recommendations: Human Papillomavirus (HPV) Vaccine. CDC ACIP Recommendations. linkSupports the U.S. HPV vaccination recommendation: routine vaccination at ages 11-12, catch-up through age 26, and shared clinical decision-making for some adults 27-45.
  6. 6.Centers for Disease Control and Prevention (2024). Condom Use: An Overview. CDC (cdc.gov/condom-use). linkSupports that condoms are highly effective against STIs spread by genital fluids but only partially protective against STIs spread by skin-to-skin contact, including HPV.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library